United States Securities and Exchange Commission · EDGAR Accession 0002087846-26-000001

Form C-AR

Annual Report — Regulation Crowdfunding
Issuer CIK 2087846
Period 2025-12-31

Vertical Longevity Pharmaceuticals, Inc.

CorporationDEIncorporated 2025IRVINE, CAvertical-longevity-pharma.com
B

Financial Condition

two fiscal years, as filed
Pre-revenue1 employee
Line itemMost recent FYPrior FYΔ
Revenue00
Cost of goods sold00
Net income(18,867)0
Total assets250
Cash & equivalents250
Accounts receivable00
Short-term debt00
Long-term debt00
Taxes paid00

Figures in USD as reported by the issuer.